165807-05-6

Basic information

• Product Name: 4-DIMETHOXYMETHYLPYRIMIDIN-2-YLAMINE
• Synonyms: 4-(DIMETHOXYMETHYL)-2-PYRIMIDINAMINE;4-DIMETHOXYMETHYLPYRIMIDIN-2-YLAMINE;4-(Dimethoxymethyl)pyrimidin-2-amine;4-DIMETHOXYMETHYLPYRIMIDIN-2-YLAMINE, 95+%;2-Amino-4-(dimethoxymethyl)pyrimidine
• CAS NO: 165807-05-6
• Molecular Formula: C₇H₁₁N₃O₂
• Molecular Weight: 169.18
• Mol File: 165807-05-6.mol

Chemical Properties

• Boiling Point: 295.3 °C at 760 mmHg
• Flash Point: 132.4 °C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 0.00154mmHg at 25°C
• Refractive Index: 1.541
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.34±0.10(Predicted)
• CAS DataBase Reference: 4-DIMETHOXYMETHYLPYRIMIDIN-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-DIMETHOXYMETHYLPYRIMIDIN-2-YLAMINE(165807-05-6)
• EPA Substance Registry System: 4-DIMETHOXYMETHYLPYRIMIDIN-2-YLAMINE(165807-05-6)

Safety Data

• Hazardous Substances Data: 165807-05-6(Hazardous Substances Data)

Usage

Uses

4-Dimethoxymethylpyrimidin-2-ylamine is a useful research chemical.

InChI:InChI=1/C7H11N3O2/c1-11-6(12-2)5-3-4-9-7(8)10-5/h3-4,6H,1-2H3,(H2,8,9,10)

Upstream product

• 67751-23-9 (E)-4-(dimethylamino)-1,1-dimethoxybut-3-en-2-one 
• 50-01-1 guanidine hydrochloride 
• 6342-56-9 Pyruvic aldehyde dimethyl acetal 
• 165807-06-7 2-Aminopyrimidine-4-carboxaldehyde 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 67751-23-9 4-(dimethylamino)-1,1-dimethoxy-but-3-en-2-one 

Downstream Products

• 180869-44-7 2-acetamidopyrimidine-4-carboxaldehyde 
• 165807-06-7 2-Aminopyrimidine-4-carboxaldehyde 
• 165806-48-4 5-(2-Aminopyrimidin-4-yl)-4-(4-fluorophenyl)-1-[3-(4-Morpholinyl)propyl]imidazole 
• 1312764-26-3 benzyl (4-formylpyrimidin-2-yl)carbamate 
• 1312764-27-4 1-[2-N-(benzyloxycarbonylamino)pyrimidin-4-yl]-2,2,2-trifluoroethanol 
• 1312764-25-2 benzyl (4-(dimethoxymethyl)pyrimidin-2-yl)carbamate 
• 1220627-33-7 1-(4-((2-aminopyrimidin-4-yl)methoxy)naphthalen-1-yl)-3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)urea 
• 2164-67-2 (2-aminopyrimidin-4-yl)methanol 
• 1229649-45-9 N-(4-((4-(3-(3-tert-butyl-1-(4-(hydroxymethyl)phenyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)methyl)pyridin-2-yl)-2-methoxyacetamide 
• 1443227-32-4 benzyl (4-(1,2,4-triazin-3-yl)pyrimidin-2-yl)carbamate 
• 1443227-28-8 benzyl (4-(4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl)pyrimidin-2-yl)carbamate 
• 1443227-29-9 2-(((benzyloxy)carbonyl)amino)pyrimidine-4-carboxylic acid 
• 1443227-30-2 methyl 2-(((benzyloxy)carbonyl)amino)pyrimidine-4-carboxylate 
• 1443227-31-3 benzyl (4-(hydrazinecarbonyl)pyrimidin-2-yl)carbamate 

Relevant articles and documents

Alkenyl Isocyanide Conjugate Additions: A Rapid Route to γ-Carbolines

Isocyanides are exceptional building blocks, the wide deployment of which in multicomponent and metal-insertion reactions belies their limited availability. The first conjugate addition/alkylation to alkenyl isocyanides is described, which addresses this deficiency. An array of organolithiums, magnesiates, enolates, and metalated nitriles add conjugately to β- and β,β-disubstituted arylsulfonyl alkenyl isocyanides to rapidly assemble diverse isocyanide scaffolds. The intermediate metalated isocyanides are efficiently trapped with electrophiles to generate substituted isocyanides incorporating contiguous tri- and tetra-substituted centers. The substituted isocyanides are ideally functionalized for elaboration into synthetic targets as illustrated by the three-step synthesis of γ-carboline N-methyl ingenine B.

HETEROCYCLIC COMPOUNDS USED AS FGFR INHIBITORS

The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, prodrug, solvent compound, polymorph, isomer or stable isotopic derivative thereof. The present invention further relates to use of the compound for the treatment or prevention of related diseases which are FGFR-mediated such as cancer, and a method for applying the compound to treat said diseases.

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.

NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.

Two new approaches towards the synthesis of annomontine using Pictet-Spengler and aza-Diels-Alder reactions

Two new routes were established for the synthesis of biologically active natural product annomontine utilizing Pictet-Spengler and aza-Diels-Alder reactions as key steps.

AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS

The invention relates to amino-heteroaryl derivatives having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.

8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula I:

8-HETEROARYLPURINE MNK2 INHIBITORS FOR TREATING METABOLIC DISORDERS

This invention relates to 8-Heteroarylpurine Mnk2 Inhibitors which are useful for the treatment and prevention of metabolic disorders such as obesity and diabetes.

Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties

The invention relates to a novel group of isonitrile compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.

Imine intermediates for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties

The invention relates to a novel group of iminc compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.